4 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 7 Phase 2, 4 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Terminated 2, Recruiting 1, Unknown 1 |
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Terminated 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Cyclophosphamide 50mg: new trials by email Literature Review of Cyclophosphamide 50mg trials Research Report on Cyclophosphamide 50mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 45 | 2026-09-01 | 2026-07-23 |
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer Maveropepimut-S, Cyclophosphamide 50mg - Platinum-resistant Epithelial Ovarian Cancer | Phase 2 | Terminated | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 16 | 2022-08-05 | 2023-09-13 |
| Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer DPX-Survivac, Letrozole 2.5mg, Cyclophosphamide 50mg - Breast Cancer | Phase 1 | Active not recruiting | Providence Health & Services | 6 | 2021-09-10 | 2026-04-13 |
| Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients Cyclophosphamide 50mg, Methotrexate - Acute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid Leukemia (AML) in Remission | Phase 3 | Recruiting | King Faisal Specialist Hospital & Research Center | 264 | 2021-08-15 | 2025-03-13 |
| The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma Cyclophosphamide 50mg, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA] - Metastatic Renal Cell Carcinoma | Phase 1 / Phase 2 | Unknown | The Christie NHS Foundation Trust | 21 | 2021-04-28 | 2022-08-23 |
| DPX-Survivac and Checkpoint Inhibitor in DLBCL DPX-Survivac, Pembrolizumab, Cyclophosphamide 50mg - Adult Diffuse Large Cell Lymphoma, Recurrent | Phase 2 | Completed | Sunnybrook Health Sciences Centre | 25 | 2018-03-13 | 2026-09-25 |
| Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide Cyclophosphamide 50mg, Pembrolizumab 100 MG in 4 ML Injection - Metastatic Breast Cancer | Phase 2 | Completed | Centre Leon Berard | 36 | 2017-06-27 | 2021-09-10 |
| Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients Cyclophosphamide 50mg, Letrozole 2.5 mg - Breast Neoplasms, Neoplasm Metastasis | Not applicable | Completed | Capital Medical University | 200 | 2015-06-01 | 2024-02-07 |
| Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Fludarabine, Cyclophosphamide 150mg, Cyclophosphamide 100mg - Anemia, Aplastic | Phase 1 / Phase 2 | Completed | Medical College of Wisconsin | 97 | 2006-01-01 | 2021-10-28 |
Breast Neoplasms (3) · Anemia, Sickle Cell (2) · Neoplasm Metastasis (2) · Anemia, Aplastic (1) · Carcinoma, Renal Cell (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Disease (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Myeloid, Acute (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1)
Capital Medical University (1) · Centre Leon Berard (1) · Columbia University (1) · ImmunoVaccine Technologies, Inc. (IMV Inc.) (1) · King Faisal Specialist Hospital & Research Center (1) · Medical College of Wisconsin (1) · Providence Health & Services (1) · St. Jude Children's Research Hospital (1) · Sunnybrook Health Sciences Centre (1) · The Christie NHS Foundation Trust (1)
United States (5) · Canada (2) · China (1) · France (1) · Puerto Rico (1) · Saudi Arabia (1) · United Kingdom (1)
Akshay Sharma, MD (1) · Mahmoud D Aljurf, MD, MPH (1) · Markus Y Mapara, MD, PhD (1) · Marwan Y Shaheen, MD (1) · Mary Horowitz, MD (1) · Neil L Berinstein, MD (1) · Riad O El Fakih, MD (1) · Sasha Stanton, MD (1) · Tom Waddell (1)
PMID 22546497, PMID 26685770, PMID 37157906, PMID 39866944
2016 (1), 2018 (1), U01HL069294 (1), U24CA076518 (1)